Results 41 to 50 of about 683 (135)

An alternative synthesis of Azilsartan: an angiotensin II receptor blocker

Current Issues in Pharmacy and Medical Sciences, 2015
This paper provides a description of an alternative, novel and commercially viable process which has been developed for the preparation of Azilsartan, a pro-drug of Azilsartan medoxomil, an angiotensin II receptor blocker.
Garaga Srinivas, Misra Nimesh C., Reddy Ambati V. Raghava, Prabahar Koilpillai Joseph, Takshinamoorthy Chandiran, Sanasi Paul Douglas, Korupolu Raghubabu   +6 more
doaj   +1 more source

Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs

Российский кардиологический журнал, 2019
Aim. To assess the possibility of azilsartan medoxomil to achieve target blood pressure (BP) (less than 130/80 mm Hg), to study angioprotective features and reduction of adipokines levels and inflammatory markers in patients with hypertension and ...
S. V. Nedogoda, E. V. Chumachek, V. V. Tsoma, A. S. Salasyuk, V. O. Smirnova, E. A. Popova   +5 more
doaj   +1 more source

Looking for an optimal antihypertensive combination. Focus on azilsartan medoxomil/chlorthalidone

Российский кардиологический журнал
The article analyzes data from clinical studies on the efficacy and safety of azilsartan medoxomil/chlorthalidone combination and its components. According to the analyzed sources, both individual components and their combination have proven their ...
M. D. Smirnova, T. V. Fofanova, F. T. Ageyev   +2 more
doaj   +1 more source

Azilsartan: Current Evidence and Perspectives in Management of Hypertension

International Journal of Hypertension, Volume 2019, Issue 1, 2019., 2019
Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP).
Akshyaya Pradhan, Ashish Tiwari, Rishi Sethi, Tomohiro Katsuya   +3 more
wiley   +1 more source

Systematic Review with Network Meta‐Analysis: Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients

International Journal of Hypertension, Volume 2019, Issue 1, 2019., 2019
Background. Hypertension (HTN) is the leading risk factor for cardiovascular mortality globally. The WHO estimates a 60% increase in Asian HTN patients between 2000 and 2025. Numerous studies have compared safety and efficacy between antihypertensive classes, but in‐class comparisons of angiotensin II receptor blockers (ARBs) in combination therapy (CT)
Dae Wook Lee, Mira Jung, Hye Won Wang, Zainah Khan, Philippe Pinton, Tomohiro Katsuya   +5 more
wiley   +1 more source

COMBINATION OF AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE: IS IT POSSIBLE TO FIGHT SYSTEMIC HYPERTENSION AND OBESITY TOGETHER?

Российский кардиологический журнал, 2017
Arterial hypertension (AH) and obesity are the main risk factors of chronic noncommunicable diseases. Adipous tissue is not only a depot for energetic compounds, but is an active endocrine organ synthetizing biologically active substances that facilitate
Yu. A. Vasyuk, E. Yu. Shupenina, E. A. Nesterova, E. I. Golubkova, V. V. Nesvetov   +4 more
doaj   +1 more source

AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY.

Frontiers in Pharmacology, 2016
Background: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high
Georgiopoulos Georgios, Vasiliki Katsi, Dimitrios Oikonomou, Georgia Vamvakou, Evangelia Koutli, Aggeliki Laina, Constantinos Tsioufis, Petros Nihoyannopoulos, Petros Nihoyannopoulos, Dimitrios Tousoulis   +9 more
doaj   +1 more source

FORMULATION AND IN VITRO EVALUATION OF AZILSARTAN MEDOXOMIL NANOSUSPENSION

International Journal of Pharmacy and Pharmaceutical Sciences, 2017
Objective: The objective of this study was to formulate and evaluate of the poorly soluble drug, azilsartan medoxomil into nanosuspension to increase the solubility and enhance the dissolution rate and then improve its bioavailability.Methods: Nanosuspension of azilsartan medoxomil was prepared using solvent-antisolvent precipitation method using PVP ...
Nizar Awish Jassem, Nawal Ayash Rajab
openaire   +2 more sources

Uptake and metabolization of four sartan drugs by eight different plants: Targeted and untargeted analyses by HPLC‐drift‐tube‐ion‐mobility quadrupole time‐of‐flight mass spectrometry

ELECTROPHORESIS, Volume 46, Issue 3-4, Page 135-142, February 2025.
Abstract In this study, we investigated the uptake and metabolization of four drugs (plus the associated prodrugs) from the sartan family by eight edible plants. Growing the plants hydroponically in a medium containing the respective drug, more than 40 phases I and II metabolites derived from the four sartan drugs could be tentatively identified.
Laura Zellner, Thomas Schiefer, Markus Himmelsbach, Franz Mlynek, Christian W. Klampfl   +4 more
wiley   +1 more source

Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and Differences

Oxidative Medicine and Cellular Longevity, Volume 2016, Issue 1, 2016., 2016
Skeletal myopathy has been identified as a major comorbidity of heart failure (HF) affecting up to 20% of ambulatory patients leading to shortness of breath, early fatigue, and exercise intolerance. Neurohumoral blockade, through the inhibition of renin angiotensin aldosterone system (RAS) and β‐adrenergic receptor blockade (β‐blockers), is a mandatory
Aline V. Bacurau, Telma F. Cunha, Rodrigo W. Souza, Vanessa A. Voltarelli, Daniele Gabriel-Costa, Patricia C. Brum, Matthew C. Zimmerman   +6 more
wiley   +1 more source